In 2024, the revenue of biotech company BioNTech SE stood at 2.75 billion euros, compared to around 17.3 billion euros in 2022. This statistic illustrates the annual revenue of BioNTech SE worldwide from 2017 to 2024. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

In 2024, total commercial revenues of biotech company BioNTech SE stood at some 2.75 billion euros, of which 2.43 billion were due to the COVID-19 vaccine. This statistic illustrates the commercial revenues of BioNTech SE worldwide from 2017 to 2024, by type. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

In 2024, the net loss of biotech company BioNTech SE was 665 million euros, compared to around 9.4 billion euros of net profit in 2022. This statistic illustrates the profit (after income taxes) of BioNTech SE from 2017 to 2024. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

In 2024, biotech company BioNTech SE reported an operating loss of around 1.3 billion euros, compared to an income of around 12.6 billion euros in 2022. This statistic illustrates the annual operating income of BioNTech from 2017 to 2024. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

In 2024, basic earnings per share of biotech company BioNTech SE stood at around -2.8 euros, compared to around 39 euros back in 2022. This statistic illustrates the annual earnings per share of BioNTech SE from 2017 to 2024. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

BioNTech SE ebit margin for the quarter ending March 31, 2025 was -48.37%. BioNTech SE average ebit margin for 2024 was -31.74%, a 163.37% increase from 2023. BioNTech SE average ebit margin for 2023 was 50.09%, a 34.39% decline from 2022. BioNTech SE average ebit margin for 2022 was 76.35%, a 1.34% decline from 2021. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

The net income of BioNTech with headquarters in Germany amounted to 930.3 million euros in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 1.1 billion euros. The trend from 2019 to 2023 shows ,however, that this increase did not happen continuously.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

BNTX BioNTech SE American Depositary Share

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

The mRNA therapeutics market is poised to witness substantial growth, with a market size of USD 12.17 billion in 2025 and projected to reach USD 61.14 billion by 2033, exhibiting a CAGR of 17.05% during the forecast period. The growth can be attributed to factors such as the increasing prevalence of infectious diseases, the rising incidence of chronic diseases, and the growing demand for personalized medicine. Additionally, the advancements in mRNA technology and the successful development of mRNA vaccines for COVID-19 have further accelerated the market growth. The mRNA therapeutics market is segmented based on application, type, end-use, and region. The infectious diseases segment is currently the largest application, owing to the high prevalence of infectious diseases worldwide and the potential of mRNA vaccines to provide effective protection. The prophylactic segment is expected to grow at a significant pace due to the increasing focus on preventive healthcare and the development of mRNA vaccines for a wider range of infectious diseases. The hospital and clinics segment is the major end-use segment, primarily due to the growing demand for mRNA-based therapies in treating various diseases in hospital settings. North America dominates the market, primarily due to the early adoption of mRNA technology, the presence of leading pharmaceutical companies, and the high prevalence of chronic diseases. The Asia Pacific region is expected to exhibit significant growth due to the increasing healthcare expenditure, the rising incidence of infectious diseases, and the growing awareness of mRNA-based therapies. The global mRNA therapeutics market is poised for exponential growth in the coming years. This cutting-edge technology holds immense promise for revolutionizing the treatment of various diseases. With an estimated market valuation of USD 20.5 billion in 2023, it is projected to reach a staggering USD 120 billion by 2030, exhibiting a remarkable CAGR of 24.1%. Recent developments include: In September 2023, Moderna, Inc. expanded its messenger ribonucleic acid research across oncology, respiratory, and rare diseases. This initiative was anticipated to fuel the company’s revenue , In August 2023, CureVac announced the commencement of dosing for the initial participant in a Phase 2 study. This study focuses on modified COVID-19 mRNA vaccine candidates developed through a collaboration with GSK Plc , In January 2023, BioNTech SE entered a strategic collaboration with the UK government to supply personalized messenger RNA cancer immunotherapies for up to 10,000 patients by 2030. This initiative positively impacted the company’s revenue , In January 2023, BioNTech SE completed the acquisition of InstaDeep Ltd. This initiative was anticipated to strengthen BioNTech’s AI-powdered drug discovery, design, and development .

Introduction

mRNA Technology Statistics: Messenger ribonucleic acid, or mRNA, was first identified in the early 1960s and serves a critical role in cellular function by transmitting genetic instructions from DNA in the cell nucleus to ribosomes, which produce proteins essential for cellular processes. Unlike traditional small-molecule drugs or biologics like monoclonal antibodies, mRNA therapeutics work by delivering instructions for cells to create specific proteins that can prevent or combat diseases. This unique approach positions mRNA as a transformative technology in medicine.

The COVID-19 pandemic accelerated mRNA’s integration into healthcare, especially with the successful development of mRNA vaccines. This success has led to a surge in mRNA-focused startups, partnerships with major pharmaceutical companies, and increased interest from big pharma in advancing mRNA-based therapeutics. Beyond COVID-19, mRNA technology shows promise in personalized cancer treatments, vaccines for malaria, influenza, hepatitis, and HIV, and therapies for genetic conditions like cystic fibrosis.

Two companies, BioNTech in Germany and Moderna in the U.S., became leaders in this field during the COVID-19 vaccine race. BioNTech, in partnership with Pfizer, developed the first widely used mRNA vaccine, while Moderna quickly followed with its own. These companies’ pioneering efforts were backed by substantial public funding, enabling the rapid development of these groundbreaking vaccines.

Looking ahead, the mRNA market is projected to expand, with estimates of approximately USD 50 billion in revenue for 2021, driven largely by COVID-19 vaccines. However, as demand for COVID-19 vaccines stabilizes, revenue is expected to decrease to USD 14 billion by 2028 before potentially rising again to USD 23 billion by 2035, as the technology finds broader applications across multiple healthcare domains.

The industry is an integral part of the pharmaceutical supply chain and the pharmaceutical sector's research and development process, with some of the largest pharma manufacturing companies across the globe being based in Europe. Over the five years through 2024, industry revenue is expected to fall at a compound annual rate of 1% to reach €613 billion, including a fall of 1.5% in 2024. Overall, an ageing population across Europe is widening the available market for manufacturers, with the rising healthcare expenditure of most EU countries supporting the industry. The COVID-19 outbreak skyrocketed the industry’s importance to the functioning of the European economy, with many manufacturers rushing to develop and patent COVID-19 vaccines and other related tests. Spiking hospital admissions during the height of the pandemic heightened demand for various pharmaceutical products. Although EU pharma manufacturers are investing heavily in new treatment research and development, boosting industry growth, they are also facing intense competition from overseas suppliers, particularly from China and India, when it comes to selling intensive-care medical products. Industry revenue is expected to grow at a compound annual rate of 4.9% over the five years through 2029 to reach €779.9 billion. The EU reform of the pharmaceuticals framework will address systemic shortages and ensure the security of the supply of critical medicinal products, boosting industry performance. The rising adoption of big data and new manufacturing practices will speed up the commercialisation of different medical treatments, supporting industry performance.

The industry is an integral part of the pharmaceutical supply chain and the pharmaceutical sector's research and development process, with some of the largest pharma manufacturing companies across the globe being based in Europe. Over the five years through 2024, industry revenue is expected to fall at a compound annual rate of 1% to reach €613 billion, including a fall of 1.5% in 2024. Overall, an ageing population across Europe is widening the available market for manufacturers, with the rising healthcare expenditure of most EU countries supporting the industry. The COVID-19 outbreak skyrocketed the industry’s importance to the functioning of the European economy, with many manufacturers rushing to develop and patent COVID-19 vaccines and other related tests. Spiking hospital admissions during the height of the pandemic heightened demand for various pharmaceutical products. Although EU pharma manufacturers are investing heavily in new treatment research and development, boosting industry growth, they are also facing intense competition from overseas suppliers, particularly from China and India, when it comes to selling intensive-care medical products. Industry revenue is expected to grow at a compound annual rate of 4.9% over the five years through 2029 to reach €779.9 billion. The EU reform of the pharmaceuticals framework will address systemic shortages and ensure the security of the supply of critical medicinal products, boosting industry performance. The rising adoption of big data and new manufacturing practices will speed up the commercialisation of different medical treatments, supporting industry performance.

The global market size of mRNA Vaccines & Therapeutics is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global mRNA Vaccines & Therapeutics Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global mRNA Vaccines & Therapeutics industry. The key insights of the report:
1.The report provides key statistics on the market status of the mRNA Vaccines & Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of mRNA Vaccines & Therapeutics industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of mRNA Vaccines & Therapeutics Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of mRNA Vaccines & Therapeutics as well as some small players. At least 13 companies are included:
* Argos Therapeutics
* AstraZeneca
* Bayer
* BioNTech
* Boehringer Ingelheim
* CRISPR Therapeutics
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of mRNA Vaccines & Therapeutics market
* Standardization Of Cancer Treatment MRNA Vaccine
* Individualized Cancer Treatment MRNA Vaccine
* Infectious Disease Treatment MRNA Vaccine
* Infection Prevention MRNA Vaccine
For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Infectious Disease
* Cancer
* Other

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

The industry is an integral part of the pharmaceutical supply chain and the pharmaceutical sector's research and development process, with some of the largest pharma manufacturing companies across the globe being based in Europe. Over the five years through 2024, industry revenue is expected to fall at a compound annual rate of 1% to reach €613 billion, including a fall of 1.5% in 2024. Overall, an ageing population across Europe is widening the available market for manufacturers, with the rising healthcare expenditure of most EU countries supporting the industry. The COVID-19 outbreak skyrocketed the industry’s importance to the functioning of the European economy, with many manufacturers rushing to develop and patent COVID-19 vaccines and other related tests. Spiking hospital admissions during the height of the pandemic heightened demand for various pharmaceutical products. Although EU pharma manufacturers are investing heavily in new treatment research and development, boosting industry growth, they are also facing intense competition from overseas suppliers, particularly from China and India, when it comes to selling intensive-care medical products. Industry revenue is expected to grow at a compound annual rate of 4.9% over the five years through 2029 to reach €779.9 billion. The EU reform of the pharmaceuticals framework will address systemic shortages and ensure the security of the supply of critical medicinal products, boosting industry performance. The rising adoption of big data and new manufacturing practices will speed up the commercialisation of different medical treatments, supporting industry performance.

According to a forecast as of March, BioNTech's and Pfizer's vaccine against COVID-19 could generate sales revenues of nearly 22 billion U.S. dollars during 2021. The BioNTech/Pfizer vaccine was the first COVID-19 vaccine to be widely approved and used. German biotech company BioNTech saw a 156 percent growth in its shares in the last 12 months as of March 2021.

Will Moderna be the big winner? Moderna is expected to be the company with the largest sales revenues from a COVID-19 vaccine. Forecasts predict that the company will make around 43 billion U.S. dollars in sales through its vaccine. Interestingly, Moderna was established in 2010 and had never made profit before the pandemic. Thus, the development of the covid vaccine based on the latest mRNA technology will mark a definitive breakthrough for the Massachusetts-based biotech company. Moderna received significant funding through taxpayer money as well as help in research and development from the National Institutes of Health.

Vaccine pricing in a pandemic Drug pricing is always a big issue and this was also the case with COVID-19 vaccines. While some companies, like AstraZeneca, stated early on that prices for the vaccine will be on a non-profit base at least as long as the pandemic is ongoing, others took a more profit-oriented approach. However, even these companies state that their current prices are low special prices, taking into account urgent public health interests, which normally would be much higher. According to several projections, COVID-19 drugs and vaccines could establish a market worth some 40 billion U.S. dollars annually.

As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide.

Global COVID-19 vaccine contracts At the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively.

Forecasted sales of COVID-19 vaccines As of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

In 2023, the company Merck had the highest profit out of all the leading pharmaceutical companies in Germany, at around *** billion euros. In second place was the company BioNTech.